Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Avexitide Acquisition Conference Call July 10, 2024 8:00 AM ET
Company Participants
Lindsey Allen - Head of Investor Relations and Communications
Justin Klee - Co-Chief Executive Officer
Joshua Cohen - Co-Chief Executive Officer
Camille Bedrosian - Chief Medical Officer
James Frates - Chief Financial Officer
Conference Call Participants
Corinne Jenkins - Goldman Sachs
Michael DiFiore - Evercore ISI
Graig Suvannavejh - Mizuho Securities
Charlie Yang - Bank of America Merrill Lynch
Joel Beatty - Robert W. Baird & Company
Ananda Ghosh - H.C. Wainwright & Co.
Operator
Good morning, ladies and gentlemen. My name is Sharon, and I will be your conference operator today. At this time, I would like to welcome everyone to the Amylyx Pharmaceuticals Conference Call to discuss the acquisition of Avexitide. All participants will be in a listen-only mode. [Operator Instructions] Please be advised that this call is being recorded at the Company's request.
I would now like to turn the call over to Lindsey Allen, Head, Investor Relations and Communications. Please proceed.
Lindsey Allen
Good morning, and thank you all for joining us today to discuss the acquisition of Avexitide, a novel GLP-1 receptor antagonist in the development for the treatment of hyperinsulinemic hypoglycemia.
With me on the call today are Josh Cohen and Justin Klee, our co-CEOs; Dr. Camille Bedrosian, our Chief Medical Officer; and Jim Frates, our Chief Financial Officer.
Before we begin, I would like to remind everyone that any statements we make or information presented on this call that are not historical facts are forward-looking statements that are based on our current beliefs, plans and expectations, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, our expectations with respect to Avexitide, AMX0035 and AMX0114, statements regarding regulatory and